CMS Finalizes Medicare Cuts for Oncologists in 2027

The Centers for Medicare and Medicaid Services finalized 2027 physician fee changes that reduce payments to oncology and radiation oncology practices.

Updated on Nov. 20, 2026 in Cancer

CMS Finalizes Medicare Cuts for Oncologists in 2027

Live Poll

Should Congress act to prevent cuts to Medicare physician payments?

The Centers for Medicare and Medicaid Services finalized the 2027 Medicare physician fee schedule, lowering conversion factors that drive payments to oncologists and radiation oncologists. CMS also cut the 340B drug reimbursement rate, shifting savings toward other outpatient services.

Why it matters

The 2026 conversion factor increase was a one-year fix that expires at year's end, so oncology practices across the United States face reduced Medicare payments in 2027. Specialty groups plan to ask Congress to ease the cut before the lame duck session ends on December 17.

The 2027 conversion factors are $32.95 for alternative payment model participants (down 1.83%) and $32.63 for non-participants (down 2.31%), while high-volume radiotherapy codes face 4%-6% reductions. The overall hematology/oncology fee impact is estimated at no less than 2%, and what Congress will do before the lame duck session ends remains unresolved.

The players

Centers for Medicare and Medicaid Services

The federal agency that administers Medicare and sets physician payment rules, including the annual fee schedule that determines what clinicians are paid.

The details

CMS finalized the 2027 Medicare physician fee schedule with conversion factor reductions that fall largely on oncologists and radiation oncologists. The agency also lowered the 340B drug reimbursement rate from 6% above average sales price to 28% below it, redistributing the savings as higher payments for other outpatient services.

Timeline

  1. 2026: A one-year 2.5% conversion factor increase took effect.

  2. Early November 2026: CMS issued final rules for 2027 payment.

  3. December 17, 2026: The lame duck session of Congress ends.

  4. 2027: Conversion factor cuts and the 340B reimbursement reduction take effect.

Health Landscape

The 2027 cuts reverse the one-year 2.5% conversion factor increase enacted for 2026, returning oncology payments to a lower baseline. The 340B reimbursement change also reflects ongoing criticism that the program has drifted beyond its original intent.

Oncology practices may face lower Medicare payments in 2027, which could affect the services and staffing available to cancer patients. The actual effect will vary depending on where a practice is located and how many alternative payment model services it provides.

The takeaway

Patients receiving cancer care should watch whether their oncology practice changes its services or participation in alternative payment models as 2027 Medicare rates take effect. Asking providers how the fee changes affect their care can help patients plan ahead.

What happens next

Congress must act before the lame duck session ends on December 17, 2026, or the conversion factor cuts take effect in 2027.

Further reading

Explore more cancer coverage on how federal payment policy is shaping treatment access.

Source note: This article includes information reported by Medscape.

Live Poll

Should Congress act to prevent cuts to Medicare physician payments?